FeaturedBiotech ETFs Are Already Benefitting from Pfizer Vaccine’s Full ApprovalBy Ian YoungAugust 23, 2021
Nasdaq Portfolio Solutions ChannelPfizer Reports Positive Earnings, Raises Forecasted Sales of VaccineBy Karrie GordonJuly 28, 2021
FeaturedAs U.K. Authorizes Pfizer Vaccine, Biotech ETFs Continue to RallyBy Ian YoungDecember 3, 2020
Equity ETF ChannelBiotech ETFs Poised for Gains after Moderna Vaccine NewsBy Ian YoungNovember 16, 2020
